Atrial Fibrillation in the Era of Emerging Cancer Therapies

Atrial fibrillation (AF) is becoming a global epidemic and is predicted to affect 6 –12 million people in the USA by 2050 and 17.9 million in Europe by 2060.1–4 Concurrently, with the advent of newer cancer therapies, global cancer survival has dramatically increased, with an expected overall survival of over 18 million persons by 2030.5 Increasingly, the profile of patients presenting with AF has disproportionately shifted to encompass patients with current or prior cancer diagnoses.
Source: European Heart Journal - Category: Cardiology Source Type: research